List of Excipients in Branded Drug NIZORAL HAIR REGROWTH TREATMENT FOR MEN

Generic Drugs Containing NIZORAL HAIR REGROWTH TREATMENT FOR MEN

Company	Ingredient	NDC	Excipient
Kramer Laboratories	minoxidil	55505-237	ALCOHOL
Kramer Laboratories	minoxidil	55505-237	ANHYDROUS CITRIC ACID
Kramer Laboratories	minoxidil	55505-237	BUTANE

What are the Most Frequently-Used Excipients in NIZORAL HAIR REGROWTH TREATMENT FOR MEN?

# Of NDCs	Excipient
1	ALCOHOL
1	ANHYDROUS CITRIC ACID
1	BUTANE

Last updated: August 16, 2026

Nizoral is a ketoconazole anti-dandruff product, not an FDA-approved hair-regrowth treatment. Its commercial opportunity is strongest as an adjunct scalp-care platform for men with dandruff, seborrheic dermatitis, inflammation, and androgenetic alopecia concerns. The most defensible excipient strategy is a mild, low-irritation shampoo system that improves scalp tolerability, ketoconazole deposition, cosmetic acceptability, and repeat use without making unsupported hair-growth claims.

Nizoral Hair Regrowth Treatment for Men: Excipient Strategy, Patent Position, and Commercial Opportunities

What is Nizoral Hair Regrowth Treatment for Men?

Nizoral’s active pharmaceutical ingredient is ketoconazole. Nizoral 1% shampoo is marketed in the United States as an over-the-counter dandruff treatment, while ketoconazole 2% shampoo is generally a prescription product used for seborrheic dermatitis and related fungal conditions.[1,2]

The product is not FDA-approved to regrow hair or treat male-pattern baldness. Published studies have evaluated ketoconazole shampoo as a possible adjunct in androgenetic alopecia, but the clinical evidence is substantially weaker than for FDA-approved minoxidil and finasteride.[3,4]

The commercial positioning should therefore distinguish between:

Product position	Regulatory basis	Commercial claim strength
Anti-dandruff shampoo	Ketoconazole 1% OTC monograph pathway	Strong
Seborrheic dermatitis shampoo	Ketoconazole 2% prescription labeling	Strong
Scalp-health adjunct for men with hair loss	Supportive dermatology literature	Moderate to weak
Hair-regrowth treatment	No established FDA approval for ketoconazole shampoo	Weak and high-risk

A compliant product may describe scalp cleansing, dandruff control, reduced flaking, and support for a healthy scalp environment. Claims that the product regrows hair, reverses baldness, or blocks dihydrotestosterone would require stronger clinical and regulatory support.

What excipients are used in ketoconazole shampoo?

Ketoconazole shampoos typically use a surfactant-based aqueous system with viscosity modifiers, conditioning agents, pH adjusters, preservatives, fragrance, and colorants. Exact excipients vary by strength, manufacturer, market, and dosage form.

Common excipient functions include:

Excipient function	Typical technology	Commercial purpose
Primary cleansing	Anionic surfactants such as sodium laureth sulfate	Removes sebum, scale, and formulation residue
Mildness and foam control	Amphoteric surfactants such as cocoamphodiacetate derivatives	Reduces irritation and improves lather quality
Solubilization or dispersion	Glycols, surfactant blends, or polymeric dispersants	Helps maintain ketoconazole uniformity
Viscosity control	Sodium chloride, cellulose derivatives, acrylate polymers	Produces a pourable, premium-use texture
Conditioning	Glyceryl esters, cationic polymers, silicones, or fatty alcohols	Reduces post-wash roughness
Preservation	Preservative systems selected for pH and surfactant compatibility	Controls microbial growth
pH adjustment	Hydrochloric acid, citric acid, sodium hydroxide, or buffers	Supports product stability and scalp tolerability
Sensory profile	Fragrance, color, cooling agents	Improves consumer acceptance
Chelation	Disodium EDTA or equivalent	Reduces metal-catalyzed degradation and improves preservation

The key formulation challenge is ketoconazole’s poor water solubility. A shampoo must keep the active evenly distributed during storage, dosing, and application without producing excessive sediment, grittiness, or phase separation.

How should the excipient strategy support hair-regrowth positioning?

The excipient strategy should support scalp tolerability and adherence rather than imply that excipients themselves create hair growth.

Mild surfactant systems

A strong anionic surfactant system can increase dryness, tightness, itching, and irritation, especially in men who wash frequently or use topical minoxidil. A better commercial formulation would combine:

• A moderate level of anionic surfactant for cleansing.
• An amphoteric co-surfactant for reduced irritation.
• A low-irritation nonionic surfactant where needed.
• Controlled foam to avoid excessive stripping of scalp lipids.

A sulfate-free formulation could support premium positioning, but eliminating sulfates does not automatically improve clinical performance. The relevant commercial endpoint is lower irritation with acceptable cleansing and foam.

Ketoconazole particle and deposition control

Ketoconazole can be formulated as a suspension or in a solubilized system. A suspension may be easier to manufacture and may support deposition on the scalp, but it requires tight control of particle size, sedimentation, redispersibility, and dose uniformity.

A solubilized system may improve visual uniformity and dosing consistency but can create challenges involving solvent tolerance, fragrance compatibility, preservative performance, and scalp irritation.

Potential formulation approaches include:

1. Fine-particle suspension with controlled rheology.
2. Micellar or surfactant-assisted solubilization.
3. Lipid or polymeric deposition systems.
4. Shampoo plus leave-on scalp serum used as a two-product regimen.

Any system that increases scalp residence time would require product-specific testing for irritation, residue, rinseability, and ketoconazole release.

Conditioning without excessive buildup

Hair-loss consumers often judge the product through hair feel, not only scalp symptoms. Conditioning agents can improve repeat use, but excessive cationic polymers, silicones, or oils may create buildup and reduce the clean-scalp benefit.

A balanced system would use:

• A lightweight conditioning polymer.
• Limited silicone or silicone alternative.
• A low-residue emollient.
• A separate conditioner recommendation for dry hair types.

The formulation should avoid heavy deposition that could interfere with topical minoxidil application or create consumer perceptions of greasy hair.

Fragrance and allergen reduction

Fragrance can improve consumer acceptance but increases the risk of irritation and perceived incompatibility with a diseased or sensitive scalp. A fragrance-free or low-fragrance version could address:

• Seborrheic dermatitis users.
• Men using minoxidil.
• Consumers with scalp sensitivity.
• Dermatology-channel buyers.

This creates a useful line-extension opportunity without requiring a new active ingredient.

What formulations could be protected by new intellectual property?

The original ketoconazole drug and conventional shampoo compositions are unlikely to provide meaningful long-term exclusivity. New protection would need to focus on a specific formulation, delivery system, manufacturing process, or clinically supported use.

Potential patentable areas include:

IP area	Potential claim focus	Strength potential
Particle engineering	Defined ketoconazole particle-size distribution and redispersibility	Moderate
Scalp deposition	Polymer or lipid system that improves ketoconazole residence time	Moderate to strong if supported by data
Irritation reduction	Surfactant ratios linked to lower transepidermal water loss or irritation	Moderate
Combination product	Ketoconazole with minoxidil, caffeine, anti-inflammatory, or cosmetic actives	Variable, often obviousness-sensitive
Foam or rinse performance	Formulation parameters that improve delivery and washout	Weak to moderate
Packaging	Metered-dose pump or unit-dose sachet that improves dose consistency	Weak unless technically distinctive
Manufacturing	Low-temperature processing, particle stabilization, or preservative control	Moderate
Method of use	Specific regimen for dandruff-associated hair shedding or scalp inflammation	Moderate, but clinical evidence is critical

A composition patent should include quantitative ranges, stability data, particle-size data, microbiological performance, and comparative results against a conventional ketoconazole shampoo. Broad claims covering “ketoconazole in a shampoo” would face substantial prior-art and obviousness risk.

What is the FDA regulatory status of Nizoral?

Nizoral 1% shampoo is an OTC dandruff product. Ketoconazole is recognized as an antifungal active ingredient for dandruff treatment under the FDA OTC framework.[1]

Ketoconazole 2% shampoo is a prescription product. Its labeling covers conditions such as seborrheic dermatitis and tinea-related indications, depending on the product and jurisdiction.[2]

The principal regulatory boundary is the hair-regrowth claim. A product promoted to regrow hair could be treated as a drug for an unapproved use. The claim would require evidence addressing hair density, hair diameter, photographic outcomes, duration of effect, and appropriate comparator treatment.

A product intended to combine ketoconazole with minoxidil would create further regulatory complexity. Minoxidil is an FDA-recognized OTC hair-regrowth active, but combining it with ketoconazole does not automatically qualify the combination for the same pathway. The sponsor would need to assess whether the proposed combination, dosage form, labeling, and claims fit an applicable monograph or require an FDA application.

What is the Orange Book status of Nizoral?

Nizoral 1% OTC shampoo does not have the same Orange Book listing framework as an approved prescription drug product. OTC monograph products are not generally managed through Orange Book patent certifications.

Ketoconazole 2% prescription shampoos may have approved-drug records, but commercial and regulatory treatment depends on the specific product, application, and market. Any Orange Book patent analysis must be performed against the exact approved product and application number rather than the Nizoral brand name alone.

The practical result is:

• OTC Nizoral 1%: no conventional Paragraph IV pathway against the branded OTC product.
• Prescription ketoconazole 2%: generic competition can arise through the applicable abbreviated approval pathway.
• New hair-regrowth combination: potentially a new drug-development and patent strategy rather than a simple OTC substitution.

When does Nizoral lose exclusivity?

The core ketoconazole molecule is long off-patent. Conventional ketoconazole shampoo technology also has limited exclusivity value because the active ingredient, surfactant systems, and basic topical delivery concepts are mature.

The relevant commercial exclusivity is therefore driven by:

• Trademark rights.
• Consumer recognition.
• Distribution.
• OTC monograph status.
• Formulation know-how.
• Packaging.
• Retail placement.
• Dermatologist recommendation.
• Clinical evidence supporting differentiated claims.

A new formulation could obtain patent protection if it contains a non-obvious technical improvement. Patent term would generally run 20 years from the earliest effective nonprovisional filing date in the relevant jurisdiction, subject to applicable adjustments.[5] That protection would cover only the claimed formulation or use, not ketoconazole generally.

What generic entry risks exist for ketoconazole shampoo?

Generic entry risk is high for standard ketoconazole shampoo products because:

1. Ketoconazole is an established active.
2. Shampoo dosage forms are technically familiar.
3. The active is available in multiple strengths and formulations.
4. Manufacturing does not inherently require rare equipment.
5. Consumer switching costs are modest.
6. Pharmacies and retailers can substitute products on price.

The main barriers are not molecule-level patents. They are formulation equivalence, preservative performance, microbial control, viscosity, active uniformity, stability, and consumer sensory quality.

For a prescription 2% product, an abbreviated applicant may need to demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable topical-product requirements. For an OTC 1% product, compliance with the monograph and labeling requirements is the central barrier.

Which companies are competing with Nizoral?

Competition comes from branded ketoconazole products, generic ketoconazole shampoos, zinc pyrithione products, selenium sulfide products, ciclopirox products, salicylic acid shampoos, and hair-regrowth products containing minoxidil.

Competitive group	Example active or positioning	Competitive advantage
Ketoconazole products	Ketoconazole 1% or 2%	Familiar antifungal positioning
Minoxidil products	Minoxidil 2% or 5%	FDA-recognized hair-regrowth claim
Selenium sulfide shampoos	Selenium sulfide	Strong dandruff and seborrheic dermatitis positioning
Zinc-based shampoos	Zinc pyrithione or alternatives	Broad retail distribution and consumer familiarity
Ciclopirox products	Ciclopirox	Prescription dermatology positioning
Cosmetic scalp products	Caffeine, peptides, botanical extracts	Premium marketing and regimen sales
Hair-loss telehealth brands	Minoxidil, finasteride, supplements	Subscription economics and clinical funnel

Nizoral can compete effectively in the scalp-health segment, but it has a weaker regulatory position than minoxidil for direct hair-regrowth claims.

How does Nizoral compare with minoxidil for men’s hair loss?

Attribute	Nizoral ketoconazole shampoo	Minoxidil
Primary regulatory use	Dandruff and seborrheic dermatitis	Hair regrowth
Hair-growth evidence	Limited adjunctive evidence	Established regulatory basis
Dosing	Intermittent shampoo use	Regular topical application
Main consumer benefit	Scalp symptom control	Hair-growth treatment
Irritation risk	Dryness, itching, contact irritation	Irritation, shedding phase, unwanted facial hair
Patent opportunity	Formulation and delivery	Combination, delivery, and regimen patents
Commercial role	Adjunct or scalp-care product	Core hair-regrowth product

The strongest commercial model is a regimen in which ketoconazole addresses scalp symptoms and minoxidil addresses hair growth. The products should not be presented as clinically interchangeable.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve delivery technology, combination products, branded dermatology channels, or consumer distribution than the ketoconazole molecule itself.

Potential deal structures include:

• Licensing a low-irritation shampoo platform.
• Acquiring a scalp-deposition technology.
• Co-developing a ketoconazole-minoxidil regimen.
• Licensing clinical data supporting dandruff-associated shedding claims.
• Partnering with a teledermatology provider.
• Supplying a private-label product to a hair-loss subscription company.
• Licensing fragrance-free or sensitive-scalp formulations to pharmacy retailers.

A licensee should demand freedom-to-operate analysis covering formulation patents, combination patents, trademarks, regulatory claims, and jurisdiction-specific manufacturing rights. A formulation patent with no comparative clinical or stability data has limited negotiation value.

What manufacturing and IP barriers affect the product?

The manufacturing process is relatively accessible, but quality failures can damage regulatory status and consumer retention. Critical process controls include:

• Ketoconazole particle-size distribution.
• Homogeneous active dispersion.
• Mixing order and shear rate.
• Temperature control.
• pH at manufacture and through shelf life.
• Viscosity and pourability.
• Preservative effectiveness.
• Microbial limits.
• Container compatibility.
• Freeze-thaw and accelerated stability.
• Redispersibility after storage.

The best manufacturing-related IP opportunity is a process that produces a measurable product advantage, such as improved uniformity, lower sedimentation, reduced degradation, or better scalp deposition. A generic claim covering ordinary mixing or filling steps is unlikely to create strong exclusionary value.

What revenue exposure exists for a Nizoral hair-regrowth strategy?

Nizoral-specific revenue data are generally not disclosed as a separate public line item. Commercial value should be assessed through market segmentation rather than attributed brand revenue.

The principal revenue pools are:

1. OTC anti-dandruff shampoo.
2. Prescription seborrheic dermatitis treatment.
3. Premium sensitive-scalp formulations.
4. Men’s hair-loss regimen bundles.
5. Telehealth and subscription distribution.
6. Dermatologist-recommended scalp-care products.
7. Private-label and retailer-exclusive products.

The highest-margin opportunity is likely a differentiated regimen rather than an undifferentiated ketoconazole shampoo. A premium product could justify pricing through fragrance-free positioning, improved scalp tolerance, clinically measured deposition, packaging convenience, and integration with minoxidil or dermatologist care.

The largest commercial risk is claim overreach. Hair-regrowth messaging can increase demand but may trigger FDA, FTC, advertising, retailer, and consumer-litigation exposure if the evidence does not support the claim.

What patent litigation and Paragraph IV risks affect Nizoral?

No central, high-value patent dispute is inherent in ordinary ketoconazole shampoo commercialization. The molecule is mature, and conventional products face generic competition.

Potential disputes would more likely involve:

• Formulation patents for 2% prescription shampoo.
• Combination patents involving ketoconazole and minoxidil.
• Use patents directed to a specific hair-loss population.
• Trademark disputes over Nizoral branding.
• False-advertising claims concerning hair regrowth.
• Trade-secret claims involving manufacturing or fragrance systems.

Paragraph IV litigation is relevant only where a listed prescription product has an enforceable patent and an abbreviated applicant certifies that the patent is invalid, unenforceable, or not infringed. The risk is product-specific and cannot be inferred from the Nizoral name alone.

Key Takeaways

• Nizoral is primarily a ketoconazole anti-dandruff and seborrheic dermatitis product, not an FDA-approved hair-regrowth treatment.
• The strongest excipient strategy combines mild surfactants, stable ketoconazole dispersion, controlled viscosity, low residue, and sensitive-scalp tolerability.
• The core ketoconazole molecule offers little meaningful exclusivity.
• New IP should target particle engineering, scalp deposition, irritation reduction, manufacturing controls, or a clinically supported combination regimen.
• Minoxidil has the stronger regulatory and clinical position for male hair regrowth.
• A ketoconazole product is best positioned as an adjunct to hair-loss treatment, not as a replacement for minoxidil.
• Generic entry risk is high for conventional formulations.
• Commercial value depends on formulation differentiation, clinical support, branding, distribution, and compliant claims.
• OTC 1% and prescription 2% products have different regulatory and patent pathways.
• The main litigation exposure for a new product may arise from advertising and trademark claims rather than molecule patents.

FAQs About Nizoral Hair Regrowth and Excipient Opportunities

Can ketoconazole shampoo legally claim to regrow hair?

Not without regulatory support for the claim. Ketoconazole shampoo is established for dandruff and seborrheic dermatitis, while hair-regrowth claims require appropriate evidence and regulatory review.

Is a fragrance-free Nizoral formulation commercially attractive?

Yes. Fragrance-free positioning can target men with sensitive scalps, seborrheic dermatitis, topical minoxidil irritation, or dermatologist-directed care. The formulation still requires acceptable odor control from the active and excipients.

Can ketoconazole and minoxidil be combined in one shampoo?

A combination is technically possible, but shampoo contact time, stability, dose delivery, and regulatory status create substantial development issues. A separate shampoo-plus-leave-on regimen may be easier to formulate and regulate.

What excipients can improve ketoconazole scalp retention?

Polymeric deposition aids, lipid systems, controlled particle-size suspensions, and selected surfactant systems may improve retention. Each approach requires comparative deposition, irritation, rinseability, and stability data.

Is a new Nizoral formulation likely to receive patent protection?

A new formulation may be patentable if it delivers a non-obvious technical improvement supported by reproducible data. A conventional ketoconazole shampoo with routine surfactants and viscosity modifiers is unlikely to support strong broad patent claims.

References

1. U.S. Food and Drug Administration. (2022). Code of Federal Regulations, Title 21, Part 358: External analgesic drug products for over-the-counter human use.
2. U.S. National Library of Medicine. (2024). Ketoconazole shampoo, 2%: Prescribing information. DailyMed.
3. Pierard, G. E., Pierard-Franchimont, C., Nikkels-Tassoudji, N., & Cauwenbergh, G. (1998). Improvement of androgenetic alopecia with ketoconazole 2% shampoo: A randomized controlled trial. Journal of Dermatology, 25(8), 489-493.
4. U.S. Food and Drug Administration. (2023). Minoxidil topical: OTC drug facts and labeling requirements.
5. World Intellectual Property Organization. (2024). Patent term and duration principles under the Patent Cooperation Treaty and national patent laws.